Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NAL2762
- Development stage
- Preclinical
- Lead developer
- Nal Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NAL2762 is an orally disintegrating film (ODF) formulation of nicotine being developed by NAL Pharmaceutical Group for smoking cessation. As a nicotinic acetylcholine receptor agonist, it delivers nicotine to the systemic circulation to alleviate withdrawal symptoms and reduce cravings in individuals attempting to quit smoking. The ODF technology is designed to dissolve rapidly in the mouth without the need for water, potentially providing a more convenient and faster-acting alternative to traditional nicotine replacement therapies like gums or patches. The program is currently in the preclinical stage of development.
- Other names
- Nicotine ODFNicotine
02
Targets
Nicotinic Acetylcholine Receptor
Beyond the preview
Go deeper on NAL2762.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NAL2762.